From Discovery
Immungenetics AG is a specialized research company dedicated to advancing early-stage scientific breakthroughs. We focus on financing and structuring foundational research, developing high-quality intellectual property, and preparing scientific programs for spin-out, licensing, or partnership.
Our role is to bridge the critical early gap between academic discovery and translational development by providing capital, strategic guidance, and platform validation.
Focus Areas
- Neurodegenerative diseases: Alzheimer’s, Parkinson’s, Huntington’s,
- Mitochondrial dysfunctions: Disorders of cellular energy and aging
- Autoimmune and inflammatory diseases: Molecular strategies for immunomodulation
- Metabolic syndromes and diabetes: Complex metabolic and endocrine conditions
- Longevity: Scientific approaches to healthy lifespan extension
Each of our projects is grounded in rigorous molecular science and designed to form the basis for new therapeutic concepts and future clinical development.
Our Model
Immungenetics operates as a long-term scientific and strategic enabler:
- We fund and develop early-stage research and IP
- We conduct early stage clinical trials
- We enable spin-outs, joint ventures, and out-licensing models
- We focus on scientific platforms, not single-asset development
Our mission is to build the foundations of future therapeutics by enabling the earliest and riskiest stages of innovation – from lab bench to commercial viability.
Cooperation Partners
Supported by
Get in Touch
Are you an investor, research institution, or life science partner interested in translating discovery into value?
Contact us – Immungenetics turns breakthrough science into tomorrow’s therapeutic opportunities.